Xenon Pharmaceuticals Inc. - Common Stock (XENE)

Historical Holders from Q4 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
XENE on Nasdaq
Shares outstanding
77,331,078
Price per share
$44.82
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
84,318,823
Holdings value
$3,385,111,233
% of all portfolios
0.01%
Share change
+873,660
Value change
+$50,758,243
Average buys %
+0%
Average sells %
-0%
Number of holders
217
Price from insider filings
$44.93
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Xenon Pharmaceuticals Inc. - Common Stock (XENE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 12% +12% $316,353,414 +$34,891,550 8,824,363 +12% FMR LLC 30 Jun 2025
BlackRock, Inc. 6.2% $170,563,868 4,757,709 BlackRock, Inc. 30 Jun 2025
JANUS HENDERSON GROUP PLC 5.1% $158,346,983 3,943,885 JANUS HENDERSON GROUP PLC 30 Sep 2025
WELLINGTON MANAGEMENT GROUP LLP 2.8% $68,070,019 2,174,761 Wellington Management Group LLP 30 Jun 2025
As of 30 Sep 2025, Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 217 institutional shareholders filing 13F forms. They hold 84,318,823 shares .

Top 25 institutional shareholders own 80% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 12% 8,918,907 +0.39% 0.02% $358,094,116
Avoro Capital Advisors LLC 7% 5,400,000 0% 2.8% $216,810,000
BlackRock, Inc. 6.2% 4,770,951 -11% 0% $191,553,697
Driehaus Capital Management LLC 5.4% 4,169,114 -3.8% 1.2% $167,389,927
JANUS HENDERSON GROUP PLC 5.1% 3,943,885 +10% 0.07% $158,311,659
WELLINGTON MANAGEMENT GROUP LLP 4.7% 3,609,857 +66% 0.03% $144,935,758
BRAIDWELL LP 4.7% 3,605,029 0% 4.3% $144,741,914
Capital International Investors 4.1% 3,181,493 -0% 0.02% $127,736,944
Commodore Capital LP 3.5% 2,700,000 -11% 5.3% $108,405,000
Polar Capital Holdings Plc 3.3% 2,546,766 -5.8% 0.49% $102,252,655
Holocene Advisors, LP 2.6% 1,976,553 +9.2% 0.18% $79,358,603
ALLIANCEBERNSTEIN L.P. 2.1% 1,654,417 +8.9% 0.02% $66,424,843
STATE STREET CORP 1.9% 1,466,467 +6.2% 0% $58,878,650
Affinity Asset Advisors, LLC 1.8% 1,400,000 +27% 5.2% $56,210,000
JPMORGAN CHASE & CO 1.8% 1,399,033 +11% 0% $56,171,175
MILLENNIUM MANAGEMENT LLC 1.8% 1,384,007 +57% 0.04% $55,567,881
Pictet Asset Management Holding SA 1.6% 1,262,579 -14% 0.05% $50,584,462
WESTFIELD CAPITAL MANAGEMENT CO LP 1.6% 1,206,066 +4.6% 0.2% $48,423,550
Deep Track Capital, LP 1.6% 1,200,000 -11% 1.3% $48,180,000
JENNISON ASSOCIATES LLC 1.5% 1,135,235 +63% 0.03% $45,579,686
Vestal Point Capital, LP 1.4% 1,100,000 -45% 2% $44,165,000
GEODE CAPITAL MANAGEMENT, LLC 1.3% 977,435 +0.73% 0% $39,240,615
CITADEL ADVISORS LLC 1.2% 959,098 +699% 0.03% $38,507,785
Rock Springs Capital Management LP 1.1% 851,744 -8.6% 2% $34,197,522
VANGUARD GROUP INC 1.1% 851,386 -2.5% 0% $34,183,148

Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 137,311 $6,154,088 +$4,482,677 $44.82 6
2025 Q3 84,318,823 $3,385,111,233 +$50,758,243 $40.15 217
2025 Q2 83,131,091 $2,602,180,922 +$191,395,529 $31.30 206
2025 Q1 76,712,487 $2,576,155,081 +$10,185,348 $33.55 206
2024 Q4 76,288,487 $2,990,360,179 +$29,951,117 $39.20 208
2024 Q3 74,874,891 $2,948,970,026 +$110,226 $39.37 203
2024 Q2 74,159,245 $2,891,332,046 +$26,539,830 $38.99 211
2024 Q1 73,470,358 $3,162,898,574 +$59,102,723 $43.05 219
2023 Q4 138,940 $6,411,576 +$1,698,608 $46.06 3
2023 Q3 61,316,223 $2,094,590,805 +$2,759,485 $34.16 178
2023 Q2 61,255,932 $2,358,691,186 +$10,271,230 $38.50 171
2023 Q1 61,098,066 $2,184,642,437 +$26,598,092 $35.79 159
2022 Q4 60,364,635 $2,380,155,366 +$39,315,554 $39.43 155
2022 Q3 56,652,467 $2,045,142,623 +$60,186,774 $36.10 147
2022 Q2 56,972,759 $1,733,113,951 +$241,066,358 $30.42 148
2022 Q1 49,007,746 $1,498,193,380 +$44,977,694 $30.57 126
2021 Q4 47,654,350 $1,488,726,712 +$452,311,689 $31.24 128
2021 Q3 34,091,198 $521,377,671 +$393,910 $15.28 115
2021 Q2 33,294,296 $619,929,580 +$2,294,891 $18.62 98
2021 Q1 32,940,149 $589,578,963 +$88,729,048 $17.90 88
2020 Q4 27,990,190 $430,443,842 -$1,905,169 $15.38 78
2020 Q3 27,927,587 $309,203,900 -$545,966 $11.07 79
2020 Q2 27,956,808 $350,579,052 +$8,433,273 $12.54 77
2020 Q1 27,692,215 $313,869,842 +$101,491,026 $11.34 69
2019 Q4 18,658,224 $244,608,634 +$22,906,546 $13.11 65
2019 Q3 16,092,590 $144,974,637 -$14,676,521 $9.01 52
2019 Q2 17,561,058 $173,154,992 -$1,930,170 $9.86 57
2019 Q1 17,733,113 $180,170,294 +$3,705,615 $10.16 60
2018 Q4 17,450,658 $110,112,206 -$23,321,684 $6.31 56
2018 Q3 17,678,662 $233,174,834 +$113,990,255 $13.20 59
2018 Q2 9,020,019 $82,987,000 +$29,134,582 $9.20 40
2018 Q1 6,342,246 $31,075,772 -$13,812,197 $4.90 34
2017 Q4 9,156,533 $25,870,000 -$498,228 $2.83 30
2017 Q3 9,321,689 $27,499,000 -$1,982,221 $2.95 30
2017 Q2 9,944,887 $31,325,000 -$1,129,729 $3.15 37
2017 Q1 10,076,383 $40,304,000 -$3,235,784 $4.00 36
2016 Q4 10,492,956 $80,798,000 +$2,074,527 $7.70 31
2016 Q3 9,927,644 $80,212,203 +$36,798,916 $8.10 30
2016 Q2 5,377,405 $32,047,000 -$2,511,469 $5.90 20
2016 Q1 5,691,967 $39,789,000 -$1,434,188 $6.99 24
2015 Q4 5,760,092 $46,313,000 +$2,273,762 $8.04 24
2015 Q3 5,349,369 $44,185,000 +$5,122,968 $8.26 24
2015 Q2 4,679,033 $53,949,000 +$3,173,785 $11.53 24
2015 Q1 4,449,844 $75,166,316 +$2,920,395 $16.86 23
2014 Q4 4,275,072 $83,141,000 +$74,135,921 $19.75 16